The dysregulation of this pathway has been implicated as a pivotal driver in 30% of cancers, with mechanisms involving activating mutations in PIK3CA, loss of function mutations in PTEN, excessive activation of upstream molecules, and gain-of-function mutations as well as amplification of AKT (45–47). This evidence concerns the gene AKT1 and cancer.